Figure 4.

Immune Cells in PBMCs Acquired from Patients Detect and Inform on Antigen-Specific T Lymphocyte Response

ELISPOT identifies CD8⁺ T cell responses to a given antigen after PBMCs are treated with an antigen of interest and stimulated ex vivo, leading to CD8⁺ T cell activation in response to a tumor-specific antigen and secretion of IFN-γ captured on an immobilized surface as insoluble spots that are enumerated. Tetramer analysis using MHC multimers loaded with antigen peptides detects T cells specific to a particular peptide-MHC complex in response to a TCV. Immune-monitoring relationships in response to TCVs may be used to help inform clinical decisions. Adapted from presentation by Caushi and Smith.⁹⁵